Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2016-06-06
|
GALE-301 GALE-302 (Folate Binding Protein (FBP)) |
ovarian cancer, endometrial cancer |
1-2a |
Galena Biopharma (USA - OR) |
Cancer - Oncology |
2016-06-06
|
rucaparib |
pancreatic cancer |
2 |
Clovis Oncology (USA - CO) |
Cancer - Oncology |
2016-06-06
|
NiCord® (expanded cell graft derived from an entire unit of umbilical cord blood enriched with stem cells) |
hematological malignancies |
1-2 |
Gamida Cell (Israel) |
Cancer - Oncology |
2016-06-06
|
VXM01 |
pancreatic cancer |
1-2 |
Vaximm (Switzerland - Germany) |
Cancer - Oncology |
2016-06-06
|
rucaparib |
ovarian cancer, fallopian tube cancer, primary peritoneal cancer |
2 |
Clovis Oncology (USA - CO) |
Cancer - Oncology |
2016-06-06
|
ANAVEX2-73 (tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride) |
fragile X syndrome |
preclinical |
Anavex Life Sciences (USA - NY) |
Rare diseases - Genetic diseases |
2016-06-06
|
VXM01 |
pancreatic cancer |
1 |
Vaximm (Germany) |
Cancer - Oncology |
2016-06-06
|
IMCgp100 |
melanoma |
1 |
Immunocore (UK) |
Cancer - Oncology |
2016-06-06
|
binimetinib (MEK162) |
advanced NRAS mutant melanoma |
3 |
Array BioPharma (USA - CO) |
Cancer - Oncology - Rare diseases |
2016-06-06
|
galinpepimut-S (human Wilms tumor protein 1 peptides - WT1 vaccine) |
malignant pleural mesothelioma |
2 |
SELLAS Life Sciences (Switzerland) |
Cancer - Oncology - Rare diseases |
2016-06-06
|
POL6014 |
cystic fibrosis, alpha-1 antitrypsin (AAT) deficiency |
1 |
Polyphor (Switzerland) |
Infectious diseases - Rare diseases - Respiratory diseases |
2016-06-05
|
IMAB362 in combination with epirubicin, oxaliplatin, and capecitabine |
CLDN18.2-positive, advanced, unresectable, recurrent or metastatic gastroesophageal cancer |
2 |
Ganymed Pharmaceuticals (Germany) |
Cancer - Oncology |
2016-06-05
|
Cabometyx™ (cabozantinib ) |
advanced renal cell carcinoma |
3 |
Exelixis (USA - CA) Ipsen (France) |
Cancer - Oncology |
2016-06-05
|
cobimetinib and atezolizumab |
metastatic colorectal cancer |
1b |
Genentech, a member of Roche Group (USA - CA - Switzerland) Exelixis (USA - CA) |
Cancer - Oncology |
2016-06-04
|
CRS-207 |
unresectable malignant pleural mesothelioma |
1b |
Aduro Biotech (USA - CA) |
Cancer - Oncology - Rare diseases |
2016-06-04
|
encorafenib and cetuximab |
patients with advanced BRAF-mutant colorectal cancer |
2 |
Array BioPharma (USA - CO) |
Cancer - Oncology |
2016-06-04
|
Opdivo® (nivolumab)+Yervoy® (ipilimumab) |
non-small cell lung cancer |
1b |
BMS (USA - NY) |
Cancer - Oncology |
2016-06-04
|
CDX-1401 and CDX-301 |
malignant melanoma |
2 |
Celldex Therapeutics (USA - NJ) National Cancer Institute (USA) |
Cancer - Oncology |
2016-06-04
|
OBI-822/OBI-821 (formerly OPT?822/OPT-821) |
metastatic breast cancer |
2-3 |
OBI Pharmaceuticals (Taiwan) |
Cancer - Oncology |
2016-06-04
|
PEGPH20 |
pancreatic cancer |
2 |
Halozyme Therapeutics (USA - CA) |
Cancer - Oncology |